Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250612 · ClinicalTrials.gov registry record · Phase 2
SYL040012, Treatment for Open Angle Glaucoma
A Phase 2 study, sponsored by Sylentis, S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
NCT02250612 is a Phase 2 study that has completed, run by Sylentis, S.A.. The registered enrollment target is 184 participants.
The verdict
NCT02250612, a Phase 2 study, has completed, sponsored by Sylentis, S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.
Interventions
- DRUG 1 drop of 0.375% SYL040012 (bamosiran)
- DRUG 1 drop of 0.750% SYL040012 (bamosiran)
- DRUG 1 drop of 1.125% SYL040012 (bamosiran)
- DRUG 1 drop of 1.5% SYL040012 (bamosiran)
- DRUG 1 drop of 0.5 % timolol maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250612
The ClinicalTrials.gov registry entry for NCT02250612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sylentis, S.A., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 1 drop of 0.375% SYL040012 (bamosiran) is the first listed.
NCT02250612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250612 about?
NCT02250612 is a clinical study titled "SYL040012, Treatment for Open Angle Glaucoma". The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.
What is the current status of trial NCT02250612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2014-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02250612?
The interventions under investigation include: 1 drop of 0.375% SYL040012 (bamosiran) (DRUG), 1 drop of 0.750% SYL040012 (bamosiran) (DRUG), 1 drop of 1.125% SYL040012 (bamosiran) (DRUG), 1 drop of 1.5% SYL040012 (bamosiran) (DRUG), 1 drop of 0.5 % timolol maleate (DRUG).
Who is sponsoring clinical trial NCT02250612?
This trial is sponsored by Sylentis, S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.